Business Context and Reporting Period
This Form 8-K is a current report filed by Ventrus Biosciences, Inc. (not Assembly Biosciences, Inc.) on January 13, 2012. The filing reports a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an event notification and does not contain financial statements or performance metrics.
Material Changes
On January 13, 2012, the company announced the publication of its prior Phase 2b clinical study results for iferanserin (VEN 309). The study focused on the treatment of hemorrhoid disease and was published in the peer-reviewed journal Clinical Therapeutics.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the clinical study publication. The primary purpose is to disclose the publication event and incorporate the associated press release by reference.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific clinical trial data and efficacy results.
- Confirm the publication details in Clinical Therapeutics to validate the study's peer-review status.
- Review subsequent filings for any regulatory decisions or commercialization plans regarding iferanserin.
- Note the discrepancy between the requested company name (Assembly Biosciences) and the filing registrant (Ventrus Biosciences).